Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Watch IgA nephropathy, because in the span of two weeks it went from a quiet kidney disease to one of the most competitive new markets in nephrology. Novartis just won full FDA approval for Fabhalta to slow kidney decline in IgAN, converting an earlier accelerated approval into the real thing. That puts three drugs in play almost at once. Vera's Trutakna, the first dual BAFF and APRIL inhibitor, was approved at the start of the month. Fabhalta now has a full label. And Vertex's povetacicept is under review with a November 30 decision date. IgAN is a progressive disease that damages the kidneys over years and long lacked good options. Now patients will have several, and the companies will fight over prescribers, formularies, and the data that distinguishes similar mechanisms. This is what a market looks like when the science finally cracks a disease. We flagged the Vera versus Vertex race two weeks ago when Vera beat Vertex to market. Novartis just made it a three way contest, and the November Vertex decision is the next flag on the calendar.

Now this week's thread to watch. Q2 earnings season is here, and it is the first hard numbers read on whether the industry is as healthy as the dealmaking and the mood suggest. J&J opened the season with a stumble, its shares slipping as oncology sales came in light. That is one company and one quarter, but it is a reminder that beneath the record M&A and the buzzing IPO window, the actual businesses still have to perform. Over the next two weeks the big pharmas report, and we will be listening for three things: how aggressively management signals more dealmaking, what they say about China exposure with the congressional probe fresh, and whether the GLP-1 franchises are holding their trajectory. That is our through line for the week, and we will pay it off Friday with what the prints actually revealed.

One more to keep in view. Friday's China deadline passed exactly as we said it would, with the companies' responses going to the committee rather than the public, so there was no dramatic reveal. Meanwhile the deal flow told its own story: Chinese drugmakers have now formed more than 100 licensing pacts with US firms. The politics grind on. The deals keep closing. 👉 Read Full Analysis

🔬 Nephrology

IgA nephropathy just became a three way race, and the science cracking it is the real story. NVS | VERA | VRTX

The FDA granted full approval to Novartis's Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy at risk of progression, converting an earlier accelerated approval, according to The Pharma Letter and Fierce Pharma. It lands in a market that suddenly has real competition. Vera's Trutakna won approval at the start of July as the first dual BAFF and APRIL inhibitor, and Vertex's povetacicept has a November 30 decision date. Three drugs, three mechanisms, one disease that not long ago had almost nothing. For patients, this is the payoff of years of research into the immune drivers of kidney damage. For the companies, it is the start of a commercial fight where similar mechanisms mean the winners will be decided by prescriber habit, payer coverage, and whatever data separates them. We flagged Vera beating Vertex to market two weeks ago. Novartis just turned a duel into a three way race.

📊 Earnings

J&J opened earnings season soft, and the numbers now have to back up the mood. JNJ

J&J kicked off Q2 earnings with shares slipping as oncology sales missed expectations, according to BioPharma Dive. It is a cautionary open to a season that arrives with the sector in its best spirits in years, buoyed by record dealmaking, a friendlier FDA, and a reopened IPO window. The J&J miss is a reminder that sentiment and performance are different things. The big pharmas report over the next two weeks, and the calls will test whether the optimism is earned. We are watching three things: how hard management leans into more M&A, what they say about China exposure with the probe still live, and whether the GLP-1 leaders are holding their growth. Those answers, not the mood coming out of BIO, are what tell you where the second half is really headed.

🔬 Respiratory

GSK walked away from a potential blockbuster after the data came in mixed. GSK

GSK ended development of camlipixant after mixed Phase 3 results from its CALM-1 and CALM-2 trials in refractory chronic cough, according to Fierce Biotech. Analysts had viewed the P2X3 receptor antagonist as a potential blockbuster and a key pipeline catalyst, so cutting it is a real blow. Refractory chronic cough is a stubborn, under treated condition, and camlipixant was one of the more advanced attempts to address it. The decision fits a pattern we have seen from GSK under Luke Miels this year, including walking away from its Alector neuro pact after those drugs failed: when the data disappoint, GSK cuts fast rather than throwing good money after bad. That discipline is defensible, but two abandoned late stage programs in a month puts more weight on the assets GSK is keeping, including the Nuvalent lung cancer drugs it paid $10.6B for.

🌍 China

The deadline passed quietly, and the deals kept coming.

Friday's deadline for Merck, AbbVie, Lilly, Pfizer and BMS to answer the House Select Committee on China came and went without a public reveal, exactly as we expected, since the responses go to the committee rather than the press. What is visible is the deal flow, and it has not slowed. Chinese drugmakers have now formed more than 100 licensing pacts with US companies, according to BioPharma Dive. The through line we tracked for a month holds: the political pressure is real, the responses will surface in fragments over the coming weeks, and the industry keeps signing. The fight that matters remains the Biotech Investment National Security Act, which would route these deals through Treasury review and still awaits a committee vote. That is the story to watch through the fall, not the deadline that just passed.

💉 Vaccines

Flu season prep started, aimed at last year's troublemaker. CSL

CSL Seqirus began shipping influenza vaccines for the 2026/27 US season, according to The Pharma Letter, targeting the H3N2 subclade K strain that drove last season's historic surge. Early shipping helps providers prepare, and the strain match matters, since last season's severity was tied partly to how the circulating virus diverged from the vaccine. It is a routine but important marker that the respiratory season is coming, and after a rough prior year, the strain targeting will be watched closely.

📋 Quick Hits

📋 The Week in Review

👉 Read Full Analysis

Three drugs are now converging on IgA nephropathy, and because their mechanisms overlap, the competition will be won on factors beyond the science. Here is the map.

Vera's Trutakna is the first dual BAFF and APRIL inhibitor approved, dosed once weekly by auto injector, and it has a first mover lead of a few weeks. Novartis's Fabhalta, an oral complement inhibitor, now has full approval and the advantage of Novartis's commercial scale and an oral format. Vertex's povetacicept, also targeting the BAFF and APRIL pathways, awaits a November 30 decision and would enter last but with Vertex's considerable resources behind it.

The mechanisms matter for differentiation. Fabhalta hits the complement system, a different node than the BAFF and APRIL axis that Trutakna and povetacicept target. That gives Novartis a cleaner differentiation story, while Vera and Vertex will be fighting over a more similar mechanistic space, where the distinctions come down to dosing, safety, and the proteinuria and kidney function data each can show.

The commercial read. First mover advantage is real in a market like this, where nephrologists build comfort with a drug and payers are slow to add similar agents, which favors Vera and Novartis over Vertex. But format and franchise matter too. An oral option like Fabhalta appeals where an injection does not, and Novartis and Vertex both have deeper commercial muscle than Vera. The November 30 Vertex decision is the next catalyst, and if povetacicept shows a differentiated profile it can still take share despite entering last. For investors, the read through is that IgAN is now a real market worth billions, and the value accrues to whoever wins the prescriber and payer battles, not necessarily to the best mechanism on paper. Watch the launch trajectories and the head to head data as it emerges.

💊 Three Questions for Earnings Season

J&J opening Q2 with an oncology miss is a useful splash of cold water. Here is what actually matters as the big pharmas report over the next two weeks.

First, dealmaking intentions. With four deals already clearing $10B in guaranteed proceeds and the M&A wave running hot, every large cap will be asked what they plan to buy. Listen for how aggressively management signals continued acquisitions versus returning cash. The tone sets expectations for whether the second half pace holds.

Second, China exposure. With the congressional probe fresh and the deadline just passed, analysts will press on China strategy. Watch for careful reassurance and for any hint that a company is reconsidering its China pipeline. The gap between what executives say and what their companies do, as AstraZeneca showed by signing five deals during the probe, is itself the signal.

Third, GLP-1 trajectory. For Lilly and Novo, the questions are supply, Medicare Bridge uptake, and the next generation pipeline. Evaluate projects Lilly's tirzepatide franchise becomes the biggest blockbuster ever, topping $70B by 2032. The calls test whether that path holds and whether Novo's oral push is closing the gap.

The J&J miss matters because it punctures the assumption that a rising tide lifts everyone. Sentiment is high, but individual businesses still have to execute, and oncology, one of the most competitive areas in the industry, is where misses show up first. If more large caps stumble on specific franchises this season, the narrative of a uniformly healthy sector gets more complicated, and the barbell we keep flagging, flush at the top and thin underneath, starts to look like it applies to product portfolios too, not just financing.

📊 GSK's Fast Cuts: Strength or Warning

GSK killing camlipixant after mixed Phase 3 data, weeks after walking away from its Alector neuro pact, raises a real question about the company's pipeline. Is the fast cutting a sign of discipline or of a pipeline running thin?

The case for discipline. Under Luke Miels, GSK has shown it will not sink more money into programs whose data disappoint. That is genuinely valuable. The industry is littered with companies that pushed marginal assets into expensive Phase 3 trials or launches and paid for it. Cutting camlipixant and the Alector drugs quickly preserves capital for better bets and reflects a management team willing to make hard calls.

The case for concern. Two abandoned late stage programs in a month thins the near term pipeline, and it puts enormous weight on the assets GSK is keeping. The $10.6B Nuvalent acquisition, its largest deal in a decade, now carries even more of the growth expectation. When a company cuts fast, it needs a deep bench behind the cuts, and each abandoned program raises the stakes on what remains. GSK also faces its own patent pressures, which makes replenishing the pipeline urgent.

Our read. The discipline is real and preferable to the alternative, but discipline only works if the remaining pipeline delivers. GSK is making the right individual decisions while accumulating a portfolio level risk: fewer shots on goal, more weight on each. The Nuvalent lung cancer drugs and the rest of the retained pipeline now have to carry the load. Watch the zidesamtinib and neladalkib progress closely, because they are increasingly central to the GSK growth story, and the margin for further disappointment is shrinking.

🎯 Catalyst Calendar

IgA nephropathy turned into a three way race, and the November Vertex decision is the next flag. J&J opened earnings soft, which is the thread we are watching all week. And GSK keeps cutting fast. What are you watching? Reply to this email.

👉 Visit The Pro Hub

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →